<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18220" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Benzodiazepines</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bounds</surname>
            <given-names>Connor G.</given-names>
          </name>
          <aff>Gridley Emergency Medical Services</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Connor Bounds declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18220.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Benzodiazepines are a category of medications that exert their effects on benzodiazepine receptors in the central nervous system. Certain benzodiazepines, such as alprazolam, clobazam, chlordiazepoxide, and others, are approved by the United States Food and Drug Administration (FDA). These drugs are crucial for the cessation of seizure activity,&#x000a0;as they account for 1% to 2% of United States emergency department visits annually.&#x000a0;Benzodiazepines may be administered for various indications, including, but not limited to,&#x000a0;insomnia, acute status epilepticus, induction of amnesia, agitation, and anxiety, spastic, and seizure disorders.</p>
        <p>Proficiency in the complex pharmacology of benzodiazepines&#x000a0;allows for the development of personalized treatment plans tailored to meet the unique needs of each patient.&#x000a0;This comprehensive understanding facilitates prudent decision-making in the prescription of benzodiazepines, optimizing dosage regimens while simultaneously minimizing the potential for adverse reactions.&#x000a0;This activity provides an overview of the indications, mechanism of action, safe administration, adverse effects, contraindications, toxicology, and monitoring associated with the diverse physiological possibilities&#x000a0;when using benzodiazepines in the clinical setting. This activity also highlights the crucial role of the interprofessional healthcare team in gaining&#x000a0;expertise and delivering focused, secure, and personalized care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between various benzodiazepines, recognizing their unique pharmacological profiles, dosages, and potential adverse effects.</p></list-item><list-item><p>Implement personalized treatment plans, optimizing benzodiazepine dosages based on individual patient needs and responses.</p></list-item><list-item><p>Select monitoring strategies to ensure the safe and effective use of benzodiazepines, including regular assessment of therapeutic response and potential adverse effects.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team to share insights, discuss patient cases, and ensure a holistic approach to benzodiazepine management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18220&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18220">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18220.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Benzodiazepines are a category of medications that exert their effects on benzodiazepine receptors in the central nervous system (CNS). These drugs are crucial for the cessation of seizure activity,&#x000a0;&#x000a0;as they account for 1% to 2% of United States emergency department visits annually.&#x000a0;Benzodiazepines may be administered for various indications, including, but not limited to,&#x000a0;insomnia, acute status epilepticus, induction of amnesia, agitation, and&#x000a0;anxiety, spastic, and seizure disorders.&#x000a0;The off-label use of benzodiazepines is prevalent in the field of psychiatry. Indications encompass conditions such as Tourette syndrome, delirium, delirium tremens, sleep disorders, and abnormal movements associated with medications, including tremors, tics, tardive dyskinesia, or chorea, among others.<xref ref-type="bibr" rid="article-18220.r1">[1]</xref><xref ref-type="bibr" rid="article-18220.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved&#x000a0;Indications</bold>
</p>
        <p>The United States Food and Drug Administration (FDA) has approved a few&#x000a0;benzodiazepines for the management of anxiety, seizures, and alcohol management, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Alprazolam: Alprazolam is indicated for anxiety disorders and panic disorders, including agoraphobia.<xref ref-type="bibr" rid="article-18220.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chlordiazepoxide:&#x000a0;Chlordiazepoxide is primarily indicated for the&#x000a0;management of alcohol withdrawal syndrome.<xref ref-type="bibr" rid="article-18220.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clobazam: Clobazam is indicated for seizures associated with Lennox-Gastaut syndrome.<xref ref-type="bibr" rid="article-18220.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clonazepam:&#x000a0;Clonazepam is indicated for treating&#x000a0;panic disorder and agoraphobia.<xref ref-type="bibr" rid="article-18220.r3">[3]</xref>&#x000a0;It is also indicated for the treatment of&#x000a0;myoclonic seizures and absence seizures.<xref ref-type="bibr" rid="article-18220.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clorazepate: Clorzapte is used for adjunct treatment of short-term management of anxiety disorders. It is also indicated for focal (partial) onset seizures.<xref ref-type="bibr" rid="article-18220.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diazepam: Diazepam is used&#x000a0;for&#x000a0;alcohol withdrawal management.<xref ref-type="bibr" rid="article-18220.r7">[7]</xref>&#x000a0;Rectal diazepam is also indicated for treating febrile seizures.<xref ref-type="bibr" rid="article-18220.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Estazolam: According to the American Academy of Sleep Medicine (AASM), estazolam is indicated for treating insomnia.<xref ref-type="bibr" rid="article-18220.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Flurazepam: Flurazepam is indicated for the treatment of insomnia.<xref ref-type="bibr" rid="article-18220.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lorazepam: Lorazepam is used for anxiety disorders. According to&#x000a0;American Epilepsy Society guidelines, parenteral lorazepam is one of the first-line treatments for convulsive status epilepticus.<xref ref-type="bibr" rid="article-18220.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Midazolam: Midazolam is indicated for convulsive status epilepticus and procedural sedation. Midazolam is used for sedation in mechanically ventilated patients in the MICU/SICU.<xref ref-type="bibr" rid="article-18220.r11">[11]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oxazepam: Oxazepam is indicated for anxiety disorders, and according to the ASAM (American Society of Addiction Medicine) guidelines, oxazepam is indicated for alcohol withdrawal syndrome.<xref ref-type="bibr" rid="article-18220.r12">[12]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Quazepam:&#x000a0;According to the American College&#x000a0;of Physicians, quazepam is&#x000a0;indicated&#x000a0;mainly for treating chronic insomnia in adults.<xref ref-type="bibr" rid="article-18220.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Temazepam: The AASM clinical practice guideline suggests temazepam for&#x000a0;sleep onset and sleep maintenance insomnia.<xref ref-type="bibr" rid="article-18220.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Triazolam: Triazolam is indicated primarily for&#x000a0;sleep-onset insomnia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Remimazolam: Remimazolam was approved by the FDA in 2020 and is indicated for short (&#x0003c;30 mins) procedural sedation in adults.<xref ref-type="bibr" rid="article-18220.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18220.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Benzodiazepines are a class of drugs that act upon benzodiazepine receptors in the CNS. The receptor is a protein comprised of&#x000a0;5 transmembrane subunits, which collectively shape a chloride channel in the center, namely the gamma-aminobutyric acid type A (GABA-A) receptor. These 5 subunits include 2 alpha subunits, 2 beta subunits, and 1 gamma subunit. The extracellular portions of the alpha and beta subunit proteins form a receptor site for GABA, which is an inhibitory neurotransmitter. The extracellular portions of the alpha and gamma subunit proteins form a binding site for benzodiazepines.</p>
        <p>Activation of benzodiazepine receptors causes a conformational change to a central pore, allowing chloride ions to enter the neuron. The influx of the chloride anion results in hyperpolarization of the neuron, resulting in CNS depression.<xref ref-type="bibr" rid="article-18220.r15">[15]</xref>&#x000a0;Benzodiazepines increase the frequency of the GABA-A receptor Cl<sup>&#x02013;</sup> channel opening in the presence of GABA. In the absence of GABA, benzodiazepines have no effects on GABA-A&#x000a0;receptor function.<xref ref-type="bibr" rid="article-18220.r16">[16]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> After oral administration, benzodiazepines are usually well absorbed from the gastrointestinal tract, except&#x000a0;clorazepate, which undergoes decarboxylation in gastric juice before absorption. After intramuscular (IM) injection, the absorption of diazepam or chlordiazepoxide is&#x000a0;slow, and the absorption of&#x000a0;lorazepam or midazolam&#x000a0;is&#x000a0;usually&#x000a0;quick. After intravenous (IV) administration, benzodiazepines are quickly distributed to the brain and the CNS. Midazolam is one of the most lipophilic benzodiazepines that crosses the blood-brain barrier and has a rapid onset of clinical effects.</p>
        <p><bold>Distribution:</bold>&#x000a0;The benzodiazepines and their active metabolites avidly bind to plasma proteins. Plasma protein binding is approximately 70% for alprazolam, 85% for clonazepam, and 99% for diazepam. The concentration of benzodiazepines in the cerebrospinal fluid is approximately equal to that of free drugs in plasma. Diazepam is redistributed&#x000a0;especially rapidly.</p>
        <p><bold>Metabolism:</bold>&#x000a0;The first phase of metabolism involves the formation of&#x000a0;<italic toggle="yes">N</italic>-desalkylated&#x000a0;metabolites&#x000a0;that are biologically active. Exceptions are triazolam, alprazolam and midazolam.&#x000a0;The second phase of metabolism involves hydroxylation and usually yields an active derivative.&#x000a0;The third phase of metabolism is the conjugation&#x000a0;with glucuronic acid.&#x000a0;Most benzodiazepines are metabolized extensively by hepatic CYP3A4 and CYP2C19. Lorazepam undergoes direct glucuronidation without cytochrome p450 metabolism. Consequently, lorazepam can be used in patients with hepatic dysfunction.<xref ref-type="bibr" rid="article-18220.r17">[17]</xref>&#x000a0;Remimazolam is degraded to&#x000a0;metabolite (CNS7054), which has&#x000a0;negligible hypnotic activity.<xref ref-type="bibr" rid="article-18220.r18">[18]</xref></p>
        <p><bold>Elimination:</bold> Benzodiazepines and their metabolites are primarily excreted by the kidneys.&#x000a0;Diazepam produces the active metabolites oxazepam, temazepam, and desmethyldiazepam, which further increase the drug action duration. The elimination half-life of benzodiazepines is increased in older patients&#x000a0;and patients with renal dysfunction.<xref ref-type="bibr" rid="article-18220.r19">[19]</xref></p>
      </sec>
      <sec id="article-18220.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Benzodiazepines are commonly administered via the oral and&#x000a0;IV routes. As protocol dictates, they may also be administered rectally, intranasally, and IM. For instance, intranasal or&#x000a0;IM administration may be useful in actively seizing patients where IV or oral administration cannot be safely performed. Rectal administration in pediatric patients may be used for seizure cessation when IV access has not been established.</p>
        <p>Benzodiazepine administration involves delivering incremental doses of the medication until the desired effects, such as sedation, cessation of seizure activity, and anxiolysis, are achieved. However, achieving a CNS drug concentration sufficient for the desired effect through IV administration may take 3 to 5 minutes. Consequently, sufficient time should exist between doses to avoid over-sedation.</p>
        <p>Furthermore, clinicians must ensure the availability of resuscitation and airway management equipment during the administration of benzodiazepines. Airway management equipment may include nasopharyngeal or oropharyngeal airways, bag valve masks, blind insertion airway devices, laryngeal mask airways, or endotracheal intubation as training of emergency management service providers allows. The conversion factor can be estimated using the diazepam milligram equivalency.<xref ref-type="bibr" rid="article-18220.r20">[20]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Alprazolam:</bold> For generalized anxiety disorder, initiate treatment with a dose of 0.25 to 0.5 mg, 3 times daily. The dose of alprazolam may be increased at intervals of 3 to 4 days to a daily dose of 4 mg. For panic disorders, a&#x000a0;1 to 4 mg/d dose is used. Use the minimal effective clinical dose due to the potential for dependence.<xref ref-type="bibr" rid="article-18220.r3">[3]</xref></p>
        <p><bold>Chlordiazepoxide:</bold> For alcohol withdrawal syndrome, the suggested initial dose is 50 to 100 mg, followed by repeated doses of up to 300 mg/d as needed. Adjust the dose according to the Clinical Institute Withdrawal Assessment-Alcohol revised (CIWA-Ar) protocol.<xref ref-type="bibr" rid="article-18220.r21">[21]</xref></p>
        <p><bold>Clonazepam:</bold>&#x000a0;The initial dose for adults with panic disorder is&#x000a0;0.5 mg/d.&#x000a0;The&#x000a0;maintenance&#x000a0;dose for most patients is 1 mg/d. A dosage of 0.5 mg is given 3 times daily for seizure disorders, and&#x000a0;the maximum&#x000a0;recommended daily dose is 20 mg.</p>
        <p><bold>Clobazam:</bold> For Lennox-Gastaut syndrome,&#x000a0;an adjunct to antiepileptic drugs, the initial dose is 10 mg for patients with a body weight of more than 30 kg. The dose is increased to&#x000a0;20 mg after&#x000a0;1 week. The usual maintenance dose after&#x000a0;2 weeks is&#x000a0;40 mg.&#x000a0;In patients with a body weight of &#x0003c;30 kg, the dose should be reduced to half the recommended dose. Study findings indicate that patients with seizure improvement on starting dosages of 10 to 20 mg/day of clobazam&#x000a0;may have better seizure control if&#x000a0;the dosage is increased beyond the maximum&#x000a0;recommended dosage of 40 mg/day.<xref ref-type="bibr" rid="article-18220.r5">[5]</xref></p>
        <p><bold>Clorazepate:</bold> The initial dose in patients with focal (partial) onset seizures in patients over 12 years is 7.5 mg, 3 times daily. The&#x000a0;maximum recommended dose is&#x000a0;90 mg/d.<xref ref-type="bibr" rid="article-18220.r7">[7]</xref></p>
        <p><bold>Diazepam:</bold> ASAM 2020 guidelines recommend front-loading for patients experiencing severe alcohol withdrawal (eg, CIWA-Ar &#x02265;19). A withdrawal symptom severity scale guides a front-loading regimen&#x000a0;(eg, 10 mg diazepam orally every hour if CIWA-Ar score &#x02265;10) or according to a fixed schedule (eg, 20 mg diazepam orally every 2 hours for&#x000a0;3 doses).<xref ref-type="bibr" rid="article-18220.r12">[12]</xref>&#x000a0;The recommended dose of diazepam (rectal) for febrile seizures is 0.5 mg/kg.<xref ref-type="bibr" rid="article-18220.r8">[8]</xref><xref ref-type="bibr" rid="article-18220.r22">[22]</xref></p>
        <p><bold>Estazolam:</bold> According to AASM, the dose of estazolam for sleep onset and sleep maintenance insomnia is 1 to 2 mg at bedtime.<xref ref-type="bibr" rid="article-18220.r9">[9]</xref></p>
        <p><bold>Flurazepam:</bold> Flurazepam is indicated for the treatment of insomnia.&#x000a0;The recommended dose of flurazepam is 15 mg for women and 30 mg for men.</p>
        <p><bold>Lorazepam:</bold> According to AES guidelines, IV lorazepam (0.1 mg/kg) is administered as an initial dose for convulsive status epilepticus; the maximum recommended dose is 4 mg. The dose may be repeated at 3 to 5 minutes.<xref ref-type="bibr" rid="article-18220.r10">[10]</xref></p>
        <p><bold>Midazolam:</bold> Midazolam is&#x000a0;administered 10 mg&#x000a0;IM for convulsive status epilepticus as a single dose. Midazolam is preferred for patients without IV access.&#x000a0;Intranasal midazolam (0.2 mg/kg, maximum dose, 10 mg) can be used in prehospital settings. For procedural sedation in patients &#x0003c;60, 0.5 to 2.5 mg IV should be&#x000a0;administered slowly over at least 2 minutes.&#x000a0;Clinicians should fully evaluate the sedative effect before administering another dose. In MICU/SICU, midazolam is used as an alternative agent for sedation in mechanically ventilated patients. An intermittent dosing strategy is preferred to avoid drug accumulation. The Richmond Agitation Sedation Scale (RASS) goal&#x000a0;is 0 to &#x02212;2.<xref ref-type="bibr" rid="article-18220.r11">[11]</xref><xref ref-type="bibr" rid="article-18220.r23">[23]</xref><xref ref-type="bibr" rid="article-18220.r24">[24]</xref></p>
        <p><bold>Oxazepam:</bold> For alcohol withdrawal syndrome, oxazepam is administered with a symptom-triggered dosing approach. For&#x000a0;CIWA-Ar scores between 8 and 15, 15 mg oxazepam is administered and 30 mg oxazepam is given&#x000a0;for CIWA-Ar &#x0003e;15.<xref ref-type="bibr" rid="article-18220.r12">[12]</xref></p>
        <p><bold>Quazepam:</bold>&#x000a0;Quazepam is suggested as an alternative drug for sleep onset and sleep maintenance insomnia. The recommended dose is 7.5 mg/d at bedtime. The dose of quazepam can be increased to 15 mg, but&#x000a0;the drug has a long half-life; hence, concern exists regarding accumulation and daytime impairment.<xref ref-type="bibr" rid="article-18220.r13">[13]</xref></p>
        <p><bold>Temazepam:</bold>&#x000a0;The AASM Clinical Practice Guideline recommends temazepam for&#x000a0;sleep onset and sleep maintenance insomnia. The recommended dose is&#x000a0;7.5 to 15 mg daily at bedtime. Temazepam improves&#x000a0;total sleep time, decreases sleep latency, and improves sleep quality. According to the American College of Physicians (ACP) guidelines, all patients with chronic insomnia should receive cognitive behavioral therapy as the initial treatment intervention.<xref ref-type="bibr" rid="article-18220.r9">[9]</xref><xref ref-type="bibr" rid="article-18220.r13">[13]</xref></p>
        <p><bold>Triazolam:</bold> Triazolam is indicated primarily for&#x000a0;sleep-onset insomnia. The recommended dose is&#x000a0;0.125 to 0.25 mg daily at bedtime. Limit the use to 4 to 8 weeks.<xref ref-type="bibr" rid="article-18220.r12">[12]</xref></p>
        <p><bold>Remimazolam:</bold> Remimazolam was approved by the FDA in 2020 and is indicated for short (&#x0003c;30 mins) procedural sedation in adults.&#x000a0;For procedural sedation in adult patients, administer 5 mg IV remimazolam over 1 minute. To maintain procedural sedation, administer 2.5 mg IV (as needed) over 15 seconds. For induction, in&#x000a0;ASA (American Society of Anesthesiologists) class III and IV patients, 2.5 to 5 mg&#x000a0;IV&#x000a0;over 1 minute is administered based on the clinical condition. To maintain procedural sedation in ASA class III and IV patients, administer 1.25 to 2.5 mg&#x000a0;IV as needed over 15 seconds. Wait for at least 2 minutes before administration of an additional dose.<xref ref-type="bibr" rid="article-18220.r14">[14]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Lorazepam and oxazepam metabolism is minimally affected by liver disease. As discussed above, lorazepam&#x000a0;is the safest empiric choice among benzodiazepines for treating&#x000a0;alcohol withdrawal syndrome and in&#x000a0;patients with hepatic impairment. Administer&#x000a0;remimazolam with caution in severe hepatic impairment.<xref ref-type="bibr" rid="article-18220.r25">[25]</xref></p>
        <p><bold>Renal impairment:</bold> In renal impairment, decreased&#x000a0;clearance and plasma protein-binding results in increased unbound (active) benzodiazepine concentration. According to a study,&#x000a0;lorazepam may be safe in patients with ESRD.&#x000a0;A risk of accumulation exists with diazepam. Lower starting doses should be used, and the dose should be cautiously titrated to clinical response.<xref ref-type="bibr" rid="article-18220.r19">[19]</xref><xref ref-type="bibr" rid="article-18220.r26">[26]</xref></p>
        <p><bold><bold>Pregnancy consideration:</bold></bold>&#x000a0;Most&#x000a0;benzodiazepines are classified as former FDA pregnancy category D medication, indicating some fetal risk, but potential benefits may allow the use in pregnant women (when fetal mortality increases by 10% for every minute of maternal seizure activity). Several studies have indicated that specific benzodiazepines (diazepam and chlordiazepoxide) may increase the risk of congenital malformations, including cleft palate in the fetus. Others, such as flurazepam and temazepam, are considered pregnancy class X drugs, as they have been shown to produce neonatal lethargy and problems in skeletal development (exencephaly and fusion or asymmetry of ribs) in neonates, respectively.</p>
        <p>All benzodiazepines should be particularly avoided during the first trimester of pregnancy.<xref ref-type="bibr" rid="article-18220.r27">[27]</xref>&#x000a0;According to the National Institute for Health and Care Excellence (NICE) guidelines, clinicians should not suggest benzodiazepines to&#x000a0;pregnant women. However, benzodiazepines can be used to manage&#x000a0;severe anxiety, agitation, and seizures. The use of benzodiazepines during pregnancy is&#x000a0;associated with neonatal hypotonia and withdrawal. Counseling is important to taper down benzodiazepines in women who are planning for pregnancy.<xref ref-type="bibr" rid="article-18220.r28">[28]</xref><xref ref-type="bibr" rid="article-18220.r29">[29]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Care should be taken in the neonatal and pre-term infant populations, as studies indicate these patients experience significant hypotension, particularly with coadministration of opioids, specifically fentanyl. A safety scoring system suggests that midazolam, lorazepam, and oxazepam can be used cautiously. The use of benzodiazepines during lactation should be avoided unless a compelling indication is present.<xref ref-type="bibr" rid="article-18220.r30">[30]</xref><xref ref-type="bibr" rid="article-18220.r31">[31]</xref><xref ref-type="bibr" rid="article-18220.r32">[32]</xref>&#x000a0;</p>
        <p><bold>Older patients:</bold>&#x000a0;The American Geriatric Society Beers Criteria identifies benzodiazepines as potentially inappropriate for older adults due to heightened sensitivity and reduced clearance. This elevated risk in&#x000a0;older patients can lead to cognitive impairment, falls, and fractures. However, reasonable use of benzodiazepines may be warranted, such as in the management of seizure disorders, alcohol withdrawal, periprocedural sedation, and severe generalized anxiety disorder.<xref ref-type="bibr" rid="article-18220.r33">[33]</xref></p>
        <p><bold>Pediatric patients:</bold> Per the American Epilepsy Society guidelines, the&#x000a0;IV administration of lorazepam and diazepam effectively stops seizures lasting at least 5 minutes. Additionally, rectal diazepam, IM midazolam, intranasal midazolam, and buccal midazolam are probably effective.<xref ref-type="bibr" rid="article-18220.r10">[10]</xref></p>
      </sec>
      <sec id="article-18220.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Benzodiazepine administration may lead to common adverse effects, including, but not limited to, respiratory depression, respiratory arrest, drowsiness, confusion, headache, syncope, nausea and vomiting, diarrhea, and tremors.</p>
        <p>In neonates, less than 1% of patients treated with benzodiazepines experience laryngospasm and bronchospasm. They may also experience ventricular arrhythmias, including ventricular bigeminy or premature ventricular contractions, vasovagal syncope, bradycardia, or tachycardia. Gastrointestinal reactions may include retching, nausea and vomiting, and excess salivation. CNS and neuromuscular adverse effects may include euphoria, hallucination, ataxia, dizziness, seizure-like activity, and paresthesia.</p>
        <p>Visual disturbances may include diplopia (&#x0201c;double vision&#x0201d;), cyclic eyelid movement, loss of balance, and difficulty focusing the eyes on objects.&#x000a0;Long-term use of benzodiazepines&#x000a0;can lead to cognitive impairment.<xref ref-type="bibr" rid="article-18220.r34">[34]</xref>&#x000a0;Rare cases of cholestatic liver injury have been reported with benzodiazepines like alprazolam, clonazepam, diazepam, and&#x000a0;flurazepam.<xref ref-type="bibr" rid="article-18220.r35">[35]</xref>&#x000a0;Hypertension, as well as hypotension, is observed with remimazolam. Monitor the blood pressure during the procedure.<xref ref-type="bibr" rid="article-18220.r36">[36]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Benzodiazepines may interact with ethanol, other benzodiazepines, and sedatives such as barbiturates, resulting in increased respiratory depression via a synergistic effect. Therefore, concomitant administration of benzodiazepines with patients under the influence of the preceding drugs should be carefully performed, with respiratory monitoring in place.<xref ref-type="bibr" rid="article-18220.r37">[37]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lorazepam and oxazepam are metabolized&#x000a0;by uridine&#x000a0;diphosphate glucuronosyltransferases (UGTs). Inducers of UGT, such as carbamazepine, phenobarbital, phenytoin, and rifampin, may induce the metabolism and decrease the efficacy.<xref ref-type="bibr" rid="article-18220.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Excessive sedation can result from concurrent administration of benzodiazepine-like midazolam, triazolam, alprazolam, or diazepam administered with strong CYP3A4 inhibitors such as itraconazole, ketoconazole,&#x000a0;grapefruit juice, clarithromycin, nefazodone, ritonavir. Avoid concurrent administration.<xref ref-type="bibr" rid="article-18220.r38">[38]</xref><xref ref-type="bibr" rid="article-18220.r39">[39]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18220.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Contraindications of benzodiazepines include&#x000a0;a known case of angle-closure glaucoma.&#x000a0;Benzodiazepines&#x000a0;have muscle relaxant effects that can affect the function of the sphincter pupillae muscle of the iris.<xref ref-type="bibr" rid="article-18220.r40">[40]</xref>&#x000a0;Benzodiazepines are also contraindicated in patients with prior&#x000a0;hypersensitivity reactions.&#x000a0;Anaphylaxis and angioedema have been reported.<xref ref-type="bibr" rid="article-18220.r41">[41]</xref>&#x000a0;Remimazolam is contraindicated in patients with a history of hypersensitivity reaction to dextran 40.<xref ref-type="bibr" rid="article-18220.r42">[42]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Concomitant use of benzodiazepines with opioids can lead to&#x000a0;sedation, severe respiratory depression, coma, and death. Avoid combination.<xref ref-type="bibr" rid="article-18220.r43">[43]</xref></p>
      </sec>
      <sec id="article-18220.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Benzodiazepines are CNS depressants specifically inhibiting respiratory drive. Therefore, careful monitoring of all vitals, especially blood pressure and respiratory rate, should be performed after the administration of benzodiazepines. In addition, waveform capnography should be considered to monitor respiratory status.&#x000a0;Though the therapeutic index of benzodiazepines is high, monitoring respiratory depression is critical. Respiratory arrest has been noted to occur with rapid injection of benzodiazepines via the&#x000a0;IV route.<xref ref-type="bibr" rid="article-18220.r44">[44]</xref></p>
        <p>Monitor for alcohol withdrawal using CIWA-Ar protocol and adjust the dose of benzodiazepines according to the score.<xref ref-type="bibr" rid="article-18220.r21">[21]</xref>&#x000a0;Patients receiving parenteral lorazepam or diazepam&#x000a0;for alcohol withdrawal should be monitored for signs of hyponatremia and metabolic acidosis, as the IV formulation contains&#x000a0;propylene glycol.<xref ref-type="bibr" rid="article-18220.r12">[12]</xref>&#x000a0;Monitor RASS in patients administered benzodiazepines in mechanically ventilated patients. According to the Society of Critical Care Medicine (SCCM) guidelines, an individualized patient-centered approach should be used to prevent oversedation.<xref ref-type="bibr" rid="article-18220.r23">[23]</xref><xref ref-type="bibr" rid="article-18220.r24">[24]</xref><xref ref-type="bibr" rid="article-18220.r45">[45]</xref></p>
        <p>Healthcare professionals&#x000a0;can use prescription drug monitoring programs to identify&#x000a0;benzodiazepine misuse.<xref ref-type="bibr" rid="article-18220.r46">[46]</xref>&#x000a0;Benzodiazepines are DEA-Scheduled IV drugs; flunitrazepam is unique among benzodiazepines, which are under Schedule IV but have Schedule I penalties.</p>
      </sec>
      <sec id="article-18220.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Patients may exhibit extreme sedation, cognitive impairment, and ataxia, often accompanied by slurred speech. Respiratory depression represents a critical concern, necessitating prompt medical intervention. Cardiovascular effects, such as hypotension and bradycardia, further underscore the systemic consequences of benzodiazepine toxicity.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Benzodiazepine&#x000a0;overdose requires&#x000a0;managing&#x000a0;the airway, breathing, and circulation according to the American Heart Association (AHA) guidelines.<xref ref-type="bibr" rid="article-18220.r47">[47]</xref>&#x000a0;Flumazenil is a GABA-A receptor antagonist, acting to reverse the sedative effects of benzodiazepines. Flumazenil functions through competitive inhibition of the alpha-gamma subunit of the GABA-A receptor. Flumazenil administration should be prudent, as it may precipitate withdrawal seizures. Of note, one multicenter trial found that patients with excessive benzodiazepine ingestion could become &#x0201c;re-sedated&#x0201d; after flumazenil began to wear off.</p>
        <p>Naloxone may also be administered if patient history/presentation suggests that opioids were taken along with benzodiazepines and the patient is experiencing signs of respiratory distress/arrest. However, naloxone doses may be smaller than the standard 0.4 mg in suspected benzodiazepine and opioid co-ingestion. Doses of 0.05 mg may be recommended, as a withdrawal from opioids may precipitate vomiting. This becomes an issue in sedated benzodiazepine-overdosed&#x000a0;patients, as they may be unable to protect their airways.<xref ref-type="bibr" rid="article-18220.r48">[48]</xref><xref ref-type="bibr" rid="article-18220.r49">[49]</xref>&#x000a0;The activated charcoal administration is contraindicated in benzodiazepine overdose. This is due primarily to altered mental status commonly associated with&#x000a0;benzodiazepine overdose, which&#x000a0;increases the risk of aspiration of activated charcoal.<xref ref-type="bibr" rid="article-18220.r50">[50]</xref></p>
        <p>
<bold>Recommendations&#x000a0;</bold>
</p>
        <p>The&#x000a0;AHA 2023 guidelines provide recommendations for cardiac arrest or toxicity due to benzodiazepine poisoning.&#x000a0;Isolated benzodiazepine poisoning rarely causes life-threatening hemodynamic instability or respiratory depression.&#x000a0;Flumazenil removes benzodiazepine-mediated suppression of the sympathetic system. It can lead to adverse cardiac events, including supraventricular tachycardia, ventricular dysrhythmias, and asystole, especially when coupled with other arrhythmogenic drugs or hypoxia. Flumazenil may not fully reverse respiratory depression in mixed overdoses, and the decision to administer flumazenil should consider potential concomitant opioid or CNS depressant poisoning, with naloxone often preferred.<xref ref-type="bibr" rid="article-18220.r51">[51]</xref></p>
      </sec>
      <sec id="article-18220.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Benzodiazepines are&#x000a0;commonly&#x000a0;prescribed drugs in&#x000a0;outpatient and&#x000a0;hospitalized&#x000a0;patients. Benzodiazepines are effective for sedation and anxiolysis; they also have the potential to cause harm. All healthcare professionals, including&#x000a0;clinicians who prescribe these agents, must be fully aware of the drug's&#x000a0;adverse effects, misuse, abuse, and potential to develop physical dependence. Benzodiazepines are DEA-Scheduled IV drugs. Pharmacists should perform medication reconciliation and report to clinicians in case of significant drug-drug interaction. Anesthesiologists and certified registered nurse anesthetists are crucial in procedural sedation.</p>
        <p>Nurses have an important role in monitoring patients in mechanically ventilated patients. Neurologists should be consulted for the appropriate use of benzodiazepines like clobazam for Lennox-Gastaut syndrome. Intensivists have an important&#x000a0;role when benzodiazepines are used for sedation in mechanically ventilated patients. Emergency medicine physicians and nurses should rapidly stabilize the patient in overdose.&#x000a0;When the patient is stable, the psychiatrist should be consulted. Psychiatrists play a crucial role in patients suffering from benzodiazepine use disorder. Finally, liberal prescribing of these drugs is not recommended as their abuse potential is high. Furthermore, the DEA has been cracking down on healthcare professionals who prescribe these agents without a valid reason and proper documentation.<xref ref-type="bibr" rid="article-18220.r52">[52]</xref><xref ref-type="bibr" rid="article-18220.r53">[53]</xref>&#x000a0;</p>
        <p>Benzodiazepine therapy requires the collaborative approach of an interprofessional healthcare team of clinicians,&#x000a0;specialists, pharmacists, and&#x000a0;specialty-trained nurses working together to accomplish optimal patient outcomes. A study concluded that interprofessional&#x000a0;team-based models that include clinical pharmacists and primary care physicians for anxiety and insomnia could&#x000a0;assist in optimizing therapy and minimizing the risk associated with benzodiazepine use.<xref ref-type="bibr" rid="article-18220.r54">[54]</xref></p>
      </sec>
      <sec id="article-18220.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18220&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18220">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18220/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18220">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18220.s11">
        <title>References</title>
        <ref id="article-18220.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maust</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Solway</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kirch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Malani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prescription and Nonprescription Sleep Product Use Among Older Adults in the United States.</article-title>
            <source>Am J Geriatr Psychiatry</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-41</page-range>
            <pub-id pub-id-type="pmid">30409547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2018</year>
            <month>Oct</month>
            <day>16</day>
            <volume>79</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">30403446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garakani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murrough</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Freire</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Thom</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Buono</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Iosifescu</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.</article-title>
            <source>Front Psychiatry</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>595584</fpage>
            <pub-id pub-id-type="pmid">33424664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>March</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Twilla</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Reaves</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Slayton</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bergeron</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sakaan</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Lorazepam versus chlordiazepoxide for the treatment of alcohol withdrawal syndrome and prevention of delirium tremens in general medicine ward patients.</article-title>
            <source>Alcohol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>81</volume>
            <fpage>56</fpage>
            <page-range>56-60</page-range>
            <pub-id pub-id-type="pmid">31176787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isojarvi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gidal</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.</article-title>
            <source>Epilepsy Behav</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>78</volume>
            <fpage>149</fpage>
            <page-range>149-154</page-range>
            <pub-id pub-id-type="pmid">29202277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Igwe</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bragazzi</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Lattanzi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clonazepam monotherapy for treating people with newly diagnosed epilepsy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Nov</month>
            <day>19</day>
            <volume>2019</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">31742671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gates</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>118</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-86</page-range>
            <pub-id pub-id-type="pmid">18384456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiang</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YI</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Rectal diazepam solution is as good as rectal administration of intravenous diazepam in the first-aid cessation of seizures in children with intractable epilepsy.</article-title>
            <source>Pediatr Neonatol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-3</page-range>
            <pub-id pub-id-type="pmid">21385654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sateia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Buysse</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-349</page-range>
            <pub-id pub-id-type="pmid">27998379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jagoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</article-title>
            <source>Epilepsy Curr</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-61</page-range>
            <pub-id pub-id-type="pmid">26900382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devlin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Skrobik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>G&#x000e9;linas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Needham</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Slooter</surname>
                <given-names>AJC</given-names>
              </name>
              <name>
                <surname>Pandharipande</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Weinhouse</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Nunnally</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rochwerg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Balas</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>van den Boogaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bosma</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Brummel</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Chanques</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Denehy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drouot</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Joffe</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kho</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kress</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lanphere</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McKinley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neufeld</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Payen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pun</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Puntillo</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Riker</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BRH</given-names>
              </name>
              <name>
                <surname>Shehabi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Szumita</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Centofanti</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nikayin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Misak</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kiedrowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alhazzani</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>9</issue>
            <fpage>e825</fpage>
            <page-range>e825-e873</page-range>
            <pub-id pub-id-type="pmid">30113379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <article-title>The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.</article-title>
            <source>J Addict Med</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>14</volume>
            <issue>3S Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-72</page-range>
            <pub-id pub-id-type="pmid">32511109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qaseem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kansagara</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Forciea</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denberg</surname>
                <given-names>TD</given-names>
              </name>
              <collab>Clinical Guidelines Committee of the American College of Physicians</collab>
            </person-group>
            <article-title>Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians.</article-title>
            <source>Ann Intern Med</source>
            <year>2016</year>
            <month>Jul</month>
            <day>19</day>
            <volume>165</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-33</page-range>
            <pub-id pub-id-type="pmid">27136449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilpatrick</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>690875</fpage>
            <pub-id pub-id-type="pmid">34354587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poisbeau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gazzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Calvel</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Anxiolytics targeting GABA<sub>A</sub> receptors: Insights on etifoxine.</article-title>
            <source>World J Biol Psychiatry</source>
            <year>2018</year>
            <volume>19</volume>
            <issue>sup1</issue>
            <fpage>S36</fpage>
            <page-range>S36-S45</page-range>
            <pub-id pub-id-type="pmid">30204559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sigel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Steinmann</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Structure, function, and modulation of GABA(A) receptors.</article-title>
            <source>J Biol Chem</source>
            <year>2012</year>
            <month>Nov</month>
            <day>23</day>
            <volume>287</volume>
            <issue>48</issue>
            <fpage>40224</fpage>
            <page-range>40224-31</page-range>
            <pub-id pub-id-type="pmid">23038269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine pharmacology and central nervous system-mediated effects.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-23</page-range>
            <pub-id pub-id-type="pmid">23789008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sneyd</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rigby-Jones</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Remimazolam for anaesthesia or sedation.</article-title>
            <source>Curr Opin Anaesthesiol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>506</fpage>
            <page-range>506-511</page-range>
            <pub-id pub-id-type="pmid">32530890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilcock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charlesworth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Twycross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Waddington</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Worthington</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Murtagh</surname>
                <given-names>FEM</given-names>
              </name>
              <name>
                <surname>Beavis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mihalyo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kotlinska-Lemieszek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prescribing Non-Opioid Drugs in End-Stage Kidney Disease.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>776</fpage>
            <page-range>776-787</page-range>
            <pub-id pub-id-type="pmid">28843456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borrelli</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Bratberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hallowell</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Greaney</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kogut</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018.</article-title>
            <source>J Manag Care Spec Pharm</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-68</page-range>
            <pub-id pub-id-type="pmid">34949119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melkonian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferm</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Assessment of a Hospital-Wide CIWA-Ar Protocol for Management of Alcohol Withdrawal Syndrome.</article-title>
            <source>Mayo Clin Proc Innov Qual Outcomes</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>344</fpage>
            <page-range>344-349</page-range>
            <pub-id pub-id-type="pmid">31485573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghazavi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nasiri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yaghini</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Soltani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Oral Diazepam in Febrile Seizures Following Acellular Pertussis Vaccination.</article-title>
            <source>Adv Biomed Res</source>
            <year>2019</year>
            <volume>8</volume>
            <fpage>29</fpage>
            <pub-id pub-id-type="pmid">31114769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kress</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Pohlman</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>May</month>
            <day>18</day>
            <volume>342</volume>
            <issue>20</issue>
            <fpage>1471</fpage>
            <page-range>1471-7</page-range>
            <pub-id pub-id-type="pmid">10816184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Mailloux</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hoskins</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Pun</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Orun</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stollings</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kiehl</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Duprey</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>O'Neal</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gropper</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Guntupalli</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Stashenko</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Brummel</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Dittus</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Ely</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Pandharipande</surname>
                <given-names>PP</given-names>
              </name>
              <collab>MENDS2 Study Investigators</collab>
            </person-group>
            <article-title>Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Apr</month>
            <day>15</day>
            <volume>384</volume>
            <issue>15</issue>
            <fpage>1424</fpage>
            <page-range>1424-1436</page-range>
            <pub-id pub-id-type="pmid">33528922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershkovich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ribeyre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McNeill</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome.</article-title>
            <source>Drugs Context</source>
            <year>2015</year>
            <volume>4</volume>
            <fpage>212287</fpage>
            <pub-id pub-id-type="pmid">26322116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wyne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cuerden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Opioid and benzodiazepine use in end-stage renal disease: a systematic review.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>326</fpage>
            <page-range>326-33</page-range>
            <pub-id pub-id-type="pmid">21071517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Creeley</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes.</article-title>
            <source>Brain Sci</source>
            <year>2019</year>
            <month>Sep</month>
            <day>14</day>
            <volume>9</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31540060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <source>Antenatal and postnatal mental health: clinical management and service guidance</source>
            <publisher-name>National Institute for Health and Care Excellence (NICE)</publisher-name>
            <publisher-loc>London</publisher-loc>
            <year>2018</year>
            <month>04</month>
            <pub-id pub-id-type="pmid">31990493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shyken</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Babbar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Babbar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Forinash</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines in Pregnancy.</article-title>
            <source>Clin Obstet Gynecol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>156</fpage>
            <page-range>156-167</page-range>
            <pub-id pub-id-type="pmid">30628916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <chapter-title>Lorazepam</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <chapter-title>Midazolam</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uguz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation.</article-title>
            <source>Am J Ther</source>
            <string-date>2021 Jan-Feb 01</string-date>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>e118</fpage>
            <page-range>e118-e126</page-range>
            <pub-id pub-id-type="pmid">30601177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crowe</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Stranks</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis.</article-title>
            <source>Arch Clin Neuropsychol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>901</fpage>
            <page-range>901-911</page-range>
            <pub-id pub-id-type="pmid">29244060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <chapter-title>Benzodiazepines</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31643621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shirley</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Remimazolam: A Review in Procedural Sedation.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>81</volume>
            <issue>10</issue>
            <fpage>1193</fpage>
            <page-range>1193-1201</page-range>
            <pub-id pub-id-type="pmid">34196946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weaver</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Prescription Sedative Misuse and Abuse.</article-title>
            <source>Yale J Biol Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-56</page-range>
            <pub-id pub-id-type="pmid">26339207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boulenc</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nicolas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hermabessi&#x000e8;re</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zobouyan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Donazzolo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ollier</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-54</page-range>
            <pub-id pub-id-type="pmid">25374256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dresser</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Spence</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-57</page-range>
            <pub-id pub-id-type="pmid">10668858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Namkoong</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: A population-based study.</article-title>
            <source>J Psychosom Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>122</volume>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">31126405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haybarger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Giovannitti</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine Allergy With Anesthesia Administration: A Review of Current Literature.</article-title>
            <source>Anesth Prog</source>
            <year>2016</year>
            <season>Fall</season>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>160</fpage>
            <page-range>160-7</page-range>
            <pub-id pub-id-type="pmid">27585420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiratori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fukuzawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tanno</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Severe Dextran-Induced Anaphylactic Shock during Induction of Hypertension-Hypervolemia-Hemodilution Therapy following Subarachnoid Hemorrhage.</article-title>
            <source>Case Rep Crit Care</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>967560</fpage>
            <pub-id pub-id-type="pmid">26171255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aschenbrenner</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Stronger Boxed Warning for Benzodiazepines.</article-title>
            <source>Am J Nurs</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>121</volume>
            <issue>3</issue>
            <fpage>22</fpage>
            <page-range>22-23</page-range>
            <pub-id pub-id-type="pmid">33625005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatlestad</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Capnography in sedation and pain management.</article-title>
            <source>Emerg Med Serv</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>65</fpage>
            <page-range>65-9</page-range>
            <pub-id pub-id-type="pmid">15839539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medlej</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Calculated decisions: Richmond Agitation-Sedation Scale (RASS).</article-title>
            <source>Emerg Med Pract</source>
            <year>2021</year>
            <month>Mar</month>
            <day>15</day>
            <volume>23</volume>
            <issue>Suppl 3</issue>
            <fpage>CD3</fpage>
            <page-range>CD3-CD4</page-range>
            <pub-id pub-id-type="pmid">33729737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees.</article-title>
            <source>Subst Abus</source>
            <year>2021</year>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>294</fpage>
            <page-range>294-301</page-range>
            <pub-id pub-id-type="pmid">31697195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panchal</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bartos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Caba&#x000f1;as</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Donnino</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Drennan</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Kudenchuk</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Morley</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Peberdy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rittenberger</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>KM</given-names>
              </name>
              <collab>Adult Basic and Advanced Life Support Writing Group</collab>
            </person-group>
            <article-title>Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</article-title>
            <source>Circulation</source>
            <year>2020</year>
            <month>Oct</month>
            <day>20</day>
            <volume>142</volume>
            <issue>16_suppl_2</issue>
            <fpage>S366</fpage>
            <page-range>S366-S468</page-range>
            <pub-id pub-id-type="pmid">33081529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallo</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hulse</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data.</article-title>
            <source>J Psychopharmacol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>211</fpage>
            <page-range>211-220</page-range>
            <pub-id pub-id-type="pmid">33426982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivilotti</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil, naloxone and the 'coma cocktail'.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>428</fpage>
            <page-range>428-36</page-range>
            <pub-id pub-id-type="pmid">26469689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zellner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Prasa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>F&#x000e4;rber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoffmann-Walbeck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Genser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eyer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The Use of Activated Charcoal to Treat Intoxications.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2019</year>
            <month>May</month>
            <day>03</day>
            <volume>116</volume>
            <issue>18</issue>
            <fpage>311</fpage>
            <page-range>311-317</page-range>
            <pub-id pub-id-type="pmid">31219028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Akpunonu</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Arens</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hoyte</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Mazer-Amirshahi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Stolbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Drennan</surname>
                <given-names>IR</given-names>
              </name>
              <collab>American Heart Association</collab>
            </person-group>
            <article-title>2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</article-title>
            <source>Circulation</source>
            <year>2023</year>
            <month>Oct</month>
            <day>17</day>
            <volume>148</volume>
            <issue>16</issue>
            <fpage>e149</fpage>
            <page-range>e149-e184</page-range>
            <pub-id pub-id-type="pmid">37721023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Osler</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Should benzodiazepines be avoided?</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>138</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-90</page-range>
            <pub-id pub-id-type="pmid">30398297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Revet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yrondi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montastruc</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Good practices in prescribing benzodiazepines].</article-title>
            <source>Presse Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>872</fpage>
            <page-range>872-877</page-range>
            <pub-id pub-id-type="pmid">30385184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18220.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furbish</surname>
                <given-names>SML</given-names>
              </name>
              <name>
                <surname>Kroehl</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Trinkley</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>A Pharmacist-Physician Collaboration to Optimize Benzodiazepine Use for Anxiety and Sleep Symptom Control in Primary Care.</article-title>
            <source>J Pharm Pract</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>425</fpage>
            <page-range>425-433</page-range>
            <pub-id pub-id-type="pmid">27480874</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
